NDA For Eagle Pharmaceuticals’ Orphan Drug Ryanodex® For The Treatment Of Malignant Hyperthermia Accepted By FDA, Priority Review Granted

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“EAGLE”) (NASDAQ:EGRX) announced today that the United States Food and Drug Administration has accepted the company’s New Drug Application for Ryanodex® (dantrolene) and granted a priority review classification. The PDUFA date is July 22, 2014.

Help employers find you! Check out all the jobs and post your resume.